A vaccine comprising synthetically linked domains of choline binding protein A (CbpA) from Streptococcus pneumonia, and a new type of pneumococcus vaccine component in which a T-cell epitope (e.g. Pneulmolysin toxoid) is fused to immunogenic fragments of choline binding protein A (CbpA). This new fused vaccine component provides an easier, less costly and more efficient way to elicit an immune response to both the T-cell epitope and CbpA as compared to a mixture of separate antigens. The CbpA fragment used preferably comprises synthetically linked domains of CbpA. The CbpA peptide-pneumolysoid fusion construct is a viable broadly protective pneumococcal vaccine that potentially adds protection against other meningeal pathogens; and may be useful for treating or preventing infections such as sepsis, meningitis, and pneumonia. Also, SJ-13-0032, “YLN for Cardiac Indication,” involves using these vaccine components to avoid adverse cardiac events caused by pneumonia infections (This is co-owned with Univ. of Texas Health Science Center.) These cardiac events are common and deadly and can create what is often referred to as a "ticking time bomb" scenario.
Synthetic vaccine, Immunogenic Fusion Protein, choline binding protein, CbpA, Streptococcus pneumonia, pneumococcal infections, sepsis, meningitis, pneumonia, cardiac, YLN
Granted Patents or Published Applications
CbpA fragment (SJ-05-0036) issued May 13, 2014 as U.S. Patent No. 8,722,055; additional U.S. Appln. pending. CbpA peptide-pneumolysoid fusion construct (SJ-10-0028) pending in the U.S. and published as U.S. Pub. No. 2014/0023674.
Related Scientific References
A comparison of candidate immunogens revealing this immunogenic fusion as part of a combination that produced the best protection against pneumococcal infection was published as:
Chen A, Mann B, Gao G, Heath R, King J, Maissoneuve J, Alderson M, Tate A, Hollingshead SK, Tweten RK, Briles DE, Tuomanen EI, Paton JC. 2015. Multivalent pneumococcal protein vaccines comprising pneumolysoid with epitopes/fragments of CbpA and/or PspA elicit strong and broad protection. Clin Vaccine Immunol 22:1079 –1089. doi:10.1128/CVI.00293-15.
These patent rights are currently available for licensing. If you are interested in learning more about this opportunity, including the possibility of collaborating with St. Jude in the development of a pneumococcus vaccine, please contact our office. We are currently seeking licensing opportunities in all fields for the development of this technology.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.